16 results about "CxC chemokine" patented technology

The present invention relates to a separated chimeric antigen receptor polypeptide (CAR), wherein the CAR comprises an extracellular antigen binding domain, and the extracellular antigen binding domain comprises an antibody or antibody fragment that binds to a human CXC chemokine receptor type 5 (CXCR5) protein. The present invention further relates to nucleic acid molecules encoding the CAR of the present invention, genetically modified immune cells expressing the CAR of the present invention, preferably T cells, and the use of the cells in the treatment of medical conditions related to the presence of pathogenic cells expressing CXCR5, wherein the pathogenic cells expressing CXCR5 are preferably pathogenic mature B cells and / or memory B cells and / or pathogenic T cells and / or follicular helper T cells, particularly mature B cell non-Hodgkin lymphoma (B-NHL), T cell non-Hodgkin lymphoma, or autoantibody-dependent autoimmune diseases, preferably selected from systemic lupus erythematosus (SLE) or rheumatoid arthritis.

The present invention discloses a CXCL-BPI fusion protein that can be used for treating Gram-negative bacterial infections, a coding nucleic acid thereof, a method for expressing and preparing the same, and a use thereof in the manufacture of a pharmaceutical composition for treating Gram-negative bacterial infections. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a bioactive fragment of N-terminal domain of human BPI, and has the dual functions of both ELR+CXC chemokine and BPI, with ability of binding to LPS and directly killing Gram-negative bacteria, and also inducing chemotaxis and promoting phagocytes to target, bind to and phagocytize Gram-negative bacteria. The mechanism of action of the fusion protein can overcome Gram-negative bacterial drug resistance.

The application discloses a CXCL-BPI fusion protein which can be used for treating gram-negative bacterial infection, a coding nucleic acid of the CXCL-BPI fusion protein, an expression preparation method, and application of the CXCL-BPI fusion protein to preparation of a pharmaceutical composition for treating gram-negative bacterial infection. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a human BPI N-terminal domain functional fragment, has the functions of combining LPS, directly killing gram-negative bacteria and chemotactic cell migration, and also has the functions of promoting phagocytes to be guided to combine and phagocytize gram-negative bacteria, and the action mechanism can overcome gram-negative bacterial drug resistance.

This invention relates to the field of biological detection, and more particularly to a monoclonal antibody combination for detecting human IL-8 protein and its application. The combination comprises monoclonal antibodies 2G3 and 3H8. The heavy and light chain variable regions of monoclonal antibody 2G3 include the complementarity-determining regions shown in SEQ ID NO. 1-6; the heavy and light chain variable regions of monoclonal antibody 3H8 include the CDRs shown in SEQ ID NO. 7-12. The antibody combination of this invention exhibits high specificity and effectively avoids cross-reactivity with other CXC chemokine family members, thereby significantly reducing non-specific background interference and the risk of false positives during detection. This invention provides a high-performance, quality-controllable key tool for biological detection for non-diagnostic purposes, research on inflammatory mechanisms, and the development of related scientific reagents.

An immune response may be induced in a subject by administering to the subject a first mRNA construct encoding a homeostatic chemokine, a cytokine, or a fragment thereof, and a second antigen mRNA construct encoding an antigen. The first mRNA construct may encode a homeostatic chemokine, which is a monomeric peptide with a disulfide bridge formed by bonding between two cysteine moieties in the homeostatic chemokine. The homeostatic chemokine may be selected from the group consisting of a CXC chemokine, a CC chemokine, a CX3C chemokine, and a C chemokine. The first mRNA construct may be used as a genetic adjuvant which potentiates an immune response to a target antigen.

The invention provides application of a CXC chemokine ligand 13 as a vascular calcification diagnosis marker, and belongs to the technical field of medicines. The high expression of the CXCL13 prompts the high risk of vascular calcification, and the reagent for detecting the expression level of the CXC chemotactic factor ligand 13 can be used for preparing a vascular calcification early-warning reagent or early-warning kit. The invention studies the effect and molecular mechanism of CXCL13 in macrophages and vascular smooth muscle cells for regulating and controlling vascular calcification, provides an early intervention target for vascular calcification, and has great significance for early diagnosis and prevention of vascular calcification.

Provided herein are methods and uses of antibodies against ELR+CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+CXC chemokines for the treatment of hidradenitis suppurativa.

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and / or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and / or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and / or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and / or ADCP in Treg cells.

Small molecule CXC chemokine receptor type 4 (CXCR4) agonists are disclosed, methods of their manufacture, and uses thereof, in particular to improve healing and reduce the risk of injury for wound healing in diabetes.

Provided herein are methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa. Also provided are doses and dosing regimens for the methods and uses of antibodies against ELR+ CXC chemokines for the treatment of hidradenitis suppurativa.

The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and / or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and / or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and / or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non- internalizing) antibodies, and antibodies efficiently inducing ADCC and / or ADCP in Treg cells. Also provided are medical uses of the disclosed antibodies or conjugates and / or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.

Provided herein are methods and uses of antibodies that bind to ELR+ CXC chemokines in combination with antibodies that bind to human IL-23p19 for the treatment of ulcerative colitis. Also provided are doses and dosing regimens for the methods and uses of antibodies that bind to ELR+ CXC chemokines in combination with antibodies that bind to human IL-23p19 for the treatment of ulcerative colitis.

The present application relates to the field of biomedical technology, and in particular to an application of a molecular marker combination in radiation pneumonitis; the application includes: using the molecular marker combination as a biomarker for radiation pneumonitis, the molecular marker combination including CXC chemokine ligand 16 and / or CC chemokine ligand 24; by performing cytokine chip detection and screening on peripheral blood specimens of multiple lung cancer patients undergoing chest radiotherapy after radiotherapy, it was found that patients with high expression of CXC chemokine ligand 16 and CC chemokine ligand 24 early after radiotherapy have a higher risk of developing radiation pneumonitis in the future, and therefore the expression levels of CXC chemokine ligand 16 and CC chemokine ligand 24 can be used to make early predictions of the occurrence of radiation pneumonitis, and therefore the above-mentioned molecular marker combination may become an early prediction tool for radiation pneumonitis in clinical practice.

Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory / autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.

The invention relates to a peptide comprising an amino acid sequence X6X7X8X9X10X11X12 according to SEQ ID NO: 1, or its pharmacologically acceptable salts, derivatives and / or conjugates, wherein X6 is G or A, X7 is R or A, X8 is R or A, X9 is T or A, X10 is R or A, X11 is L or A, X12 is C or A, with the proviso that one of the amino acids at position X6, X7, X8, X9, X10, X11 or X12 may be alanine, wherein the peptide has a total length in the range of 7 to 30 amino acids, and wherein a peptide consisting of the amino acid sequence KRRPAKAWSGRRTRLCC according to SEQ ID NO: 2 is excluded. The invention further relates to a medicament comprising a peptide according to SEQ ID NO: 1 and to a use for the manufacture of a medicament.

The invention provides an anti-ELR + CXC chemotactic factor antibody or an antigen binding fragment thereof as well as a preparation method and application of the anti-ELR + CXC chemotactic factor antibody. The ELR + CXC chemotactic factor antibody or the antigen binding fragment thereof. The ELR + CXC chemotactic factor is selected from one or more of CXCL1, CXCL2, CXCL3 and CXCL8. According to the application, the antibody which is specifically combined with the ELR + CXC chemotactic factor strongly related to the disease is screened out, the antibody can block a signal channel of the ELR + CXC chemotactic factor, ERK phosphorylation and human neutrophil chemotactic activity are blocked, and a new feasible scheme is provided for treatment of inflammation, immune diseases and cancers.